SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Solid Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.92+0.39 (+7.05%)
Close on Oct 19, 2026
- Market cap
- $850.64M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.04 (+0.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $850.64M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.27
- Dividend yield
- –
- Free cash flow yield
- -22.08%
Fundamentals
- EPS, diluted
- -$1.99
- Free cash flow
- -$187.81M
- Book value per share
- $2.60
- Diluted shares
- 144M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$212.15M
Net income
–
EPS, diluted
–
Free cash flow
-$187.81M
Reported periodTrailing twelve months